Compare AbCellera Biologics Inc (ABCL) vs Hut 8 Corp (HUT) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

HUT trades at $103.78, up 6.84% today, but faces bearish technical signals with resistance at $108. The company shows strong analyst support (93.75% buy ratings) with a $129.44 consensus target, yet fundamentals reveal challenges: negative net income margin of -109.77% in 2025 and operating cash flow of -$139.23M. Recent news highlights Hut 8's pivot to AI infrastructure, closing $4.25B in project financing for data centers, signaling strategic growth amid profitability concerns.

Outlook: High growth potential from AI/data center expansion, but elevated execution risks and persistent losses warrant caution. Near-term price movement may hinge on Q2 2026 earnings (expected EPS -$0.32) and Bitcoin market volatility. Risks include competitive pressures and reliance on financing for cash flow.